Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.

MLA

Castagna, Antonella, et al. “Dolutegravir in Antiretroviral-Experienced Patients with Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study.” The Journal of Infectious Diseases, vol. 210, no. 3, Aug. 2014, pp. 354–62. EBSCOhost, https://doi.org/10.1093/infdis/jiu051.

APA

Castagna, A., Maggiolo, F., Penco, G., Wright, D., Mills, A., Grossberg, R., Molina, J.-M., Chas, J., Durant, J., Moreno, S., Doroana, M., Ait-Khaled, M., Huang, J., Min, S., Song, I., Vavro, C., Nichols, G., & Yeo, J. M. (2014). Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. The Journal of Infectious Diseases, 210(3), 354–362. https://doi.org/10.1093/infdis/jiu051

Chicago

Castagna, Antonella, Franco Maggiolo, Giovanni Penco, David Wright, Anthony Mills, Robert Grossberg, Jean-Michel Molina, et al. 2014. “Dolutegravir in Antiretroviral-Experienced Patients with Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study.” The Journal of Infectious Diseases 210 (3): 354–62. doi:10.1093/infdis/jiu051.